ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Cleveland, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Cancer

Non-Hodgkin Lymphoma trials near Cleveland, OH, USA:

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma

-T treatment.This phase 1 study will evaluate safe dose and provide initial signal of the activity of BAFF CAR-T cells against relapsed non- ...

Enrolling
Lymphoma, Non-Hodgkin Lymphoma, B-Cell
Drug: BAFF CAR-T

Phase 1

Luminary Therapeutics

Cleveland, Ohio, United States and 1 other location

ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a po-...

Enrolling
Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
Drug: ARV-393

Phase 1

Arvinas
Arvinas

Cleveland, Ohio, United States and 13 other locations

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
Relapsed B-Cell Non-Hodgkin Lymphoma
Drug: Loncastuximab Tesirine
Drug: Polatuzumab Vedotin

Phase 1

ADC Therapeutics

Cleveland, Ohio, United States and 27 other locations

in participants with relapsed or refractory (R/R) solid tumors or non-Hodgkin lymphoma (NHL).Part 2: Cohort Expansion. The...

Enrolling
Non-Hodgkin Lymphoma
Relapsed Solid Tumors
Drug: KB-0742

Phase 1, Phase 2

Kronos Bio

Cleveland, Ohio, United States and 25 other locations

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Fludarabine
Drug: JCAR017

Phase 2

Celgene
Celgene

Cleveland, Ohio, United States and 55 other locations

Recently updated

The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The ma...

Enrolling
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Drug: JNJ-90009530

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Cleveland, Ohio, United States and 14 other locations

This study will enroll approximately 160 adult participants who have relapsed or refractory (r/r) iNHL to be infused with the study treatment, axicab...

Active, not recruiting
Marginal Zone Lymphoma
Indolent Non-Hodgkin Lymphoma
Biological: axicabtagene ciloleucel
Drug: Cyclophosphamide

Phase 2

Gilead Sciences
Gilead Sciences

Cleveland, Ohio, United States and 18 other locations

This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL).T...

Enrolling
B-cell Non-Hodgkin Lymphoma (B-NHL)
Drug: Odronextamab

Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Cleveland, Ohio, United States and 137 other locations

if it works to treat the diseases under study. The diseases under study will be Renal Cell Carcinoma (RCC),Nasopharyngeal Carcinoma (NPC) and Non...

Enrolling
Non Hodgkin Lymphoma
Nasopharyngeal Carcinoma
Drug: PRO1160

Phase 1, Phase 2

ProfoundBio

Cleveland, Ohio, United States and 17 other locations

This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with rituximab in participants with CD20-positive lymphoprolifer...

Active, not recruiting
Non-Hodgkin's Lymphoma
Hematological Malignancies
Drug: ABT-263
Drug: rituximab

Phase 1

AbbVie
AbbVie

Cleveland, Ohio, United States and 5 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems